Regeneron (REGN) Hits New 52-Week High and Low at $312.80

Regeneron (NASDAQ:REGN)’s share price reached a new 52-week high and low during trading on Friday . The stock traded as low as $312.80 and last traded at $313.83, with a volume of 256639 shares changing hands. The stock had previously closed at $315.83.

Several equities analysts recently commented on REGN shares. Argus cut their target price on shares of Regeneron from $540.00 to $470.00 and set a “buy” rating for the company in a research note on Thursday, December 28th. Citigroup reiterated a “neutral” rating and set a $388.00 target price (up from $380.00) on shares of Regeneron in a research note on Tuesday, January 9th. JPMorgan Chase upped their target price on shares of Regeneron from $455.00 to $457.00 and gave the company a “neutral” rating in a research note on Wednesday, January 24th. BidaskClub upgraded shares of Regeneron from a “strong sell” rating to a “sell” rating in a research note on Friday, January 26th. Finally, Jefferies Group reiterated a “hold” rating and set a $421.00 target price on shares of Regeneron in a research note on Friday, February 2nd. Four research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and eight have given a buy rating to the stock. Regeneron currently has an average rating of “Hold” and a consensus target price of $448.72.

How to Become a New Pot Stock Millionaire

The stock has a market capitalization of $34,013.63, a PE ratio of 23.43, a PEG ratio of 1.03 and a beta of 1.46. The company has a current ratio of 3.82, a quick ratio of 3.18 and a debt-to-equity ratio of 0.11.

Regeneron (NASDAQ:REGN) last announced its earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.18 by $1.05. The business had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.50 billion. Regeneron had a net margin of 20.41% and a return on equity of 28.48%. The firm’s revenue for the quarter was up 28.9% on a year-over-year basis. During the same quarter last year, the company posted $3.04 EPS. equities research analysts expect that Regeneron will post 19.2 earnings per share for the current year.

In related news, Director Joseph L. Goldstein sold 2,000 shares of the stock in a transaction dated Monday, March 19th. The shares were sold at an average price of $350.02, for a total transaction of $700,040.00. Following the completion of the sale, the director now owns 14,000 shares in the company, valued at approximately $4,900,280. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Joseph L. Goldstein sold 1,000 shares of the stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $325.60, for a total transaction of $325,600.00. The disclosure for this sale can be found here. Insiders have sold a total of 5,000 shares of company stock valued at $1,705,640 in the last quarter. 10.80% of the stock is currently owned by corporate insiders.

Several institutional investors have recently made changes to their positions in the stock. ADAMCAPITAL Gestao de Recursos Ltda. acquired a new stake in shares of Regeneron during the 4th quarter worth about $29,252,000. Cambridge Investment Research Advisors Inc. increased its position in shares of Regeneron by 2.8% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 9,302 shares of the biopharmaceutical company’s stock worth $3,497,000 after purchasing an additional 256 shares in the last quarter. KCM Investment Advisors LLC increased its position in shares of Regeneron by 34.7% during the 4th quarter. KCM Investment Advisors LLC now owns 936 shares of the biopharmaceutical company’s stock worth $352,000 after purchasing an additional 241 shares in the last quarter. Xact Kapitalforvaltning AB increased its position in shares of Regeneron by 23.6% during the 4th quarter. Xact Kapitalforvaltning AB now owns 17,772 shares of the biopharmaceutical company’s stock worth $6,682,000 after purchasing an additional 3,397 shares in the last quarter. Finally, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp increased its position in shares of Regeneron by 16.1% during the 4th quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 65,862 shares of the biopharmaceutical company’s stock worth $24,761,000 after purchasing an additional 9,157 shares in the last quarter. Institutional investors and hedge funds own 66.40% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Regeneron (REGN) Hits New 52-Week High and Low at $312.80” was published by Week Herald and is the property of of Week Herald. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://weekherald.com/2018/04/22/regeneron-regn-hits-new-52-week-high-and-low-at-312-80.html.

Regeneron Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Receive News & Ratings for Regeneron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply